Trial
NCT02802163
Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat
Phase IWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Collaborators
Novartis; Amgen
Condition
Multiple Myeloma
Intervention
Panobinostat
Why stopped
study drug unavailable
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-04-25